Dr. Schlumbrecht on the Role of Surgical Resection in Uterine Leiomyosarcoma

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the role of surgical resection in uterine leiomyosarcoma.

A prospective clinical trial comparing surgical resection with chemotherapy in uterine leiomyosarcoma would be unlikely to complete full accrual given the rarity of the disease, says Schlumbrecht.

However, retrospective data have demonstrated a potential survival advantage for patients who underwent a complete resection, particularly in those who had negative margins following surgery, says Schlumbrecht.

As such, surgical resection is advisable in eligible patients, after which chemotherapy can be considered.